Astrazeneca (AZN) EBITDA Margin (2009 - 2026)
Astrazeneca (AZN) recorded quarterly EBITDA Margin of 3522.08% in Q1 2026, down 92.4% quarter-over-quarter from 46316.67% in Q4 2025, and down 191576.0% on a YoY basis from N/an in Q1 2025.
Astrazeneca (AZN) EBITDA Margin (2009 - 2026) Analysis & Trends
Astrazeneca's EBITDA Margin history runs 18 years deep, the most recent figure standing at 3522.08% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 191576.0% year-over-year to 3522.08%; the TTM figure through Mar 2026 stood at 11395.1% (up 1050203.0% YoY), while the FY2025 annual figure was 22.02%, down 65414.0% from the prior year.
- EBITDA Margin was 3522.08% for Q1 2026 at Astrazeneca, down from 46316.67% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 48275.0% in Q2 2024 to a low of 13.62% in Q4 2024.
- Historically, EBITDA Margin has averaged 12037.33% across 5 years, with a median of 3917.78% in 2024.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin sank 1163679 bps in 2023, then soared 4751179 bps in 2024.
- A 5-year view of EBITDA Margin shows it stood at 1084.18% in 2022, then sank by 41 bps to 642.6% in 2023, then tumbled by 102 bps to 13.62% in 2024, then soared by 340173 bps to 46316.67% in 2025, then tumbled by 92 bps to 3522.08% in 2026.
- The last three EBITDA Margin figures came in at 3522.08% (Q1 2026), 46316.67% (Q4 2025), and 23409.09% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 24.65% |
| 10 | Astrazeneca | 72.15 Bn | 64.21 Bn | 12.61 Bn | 3,522.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,522.08% |
| Dec 31, 2025 | 46,316.67% |
| Sep 30, 2025 | 23,409.09% |
| Jun 30, 2025 | 44,462.50% |
| Mar 31, 2025 | 5,437.84% |
| Dec 31, 2024 | -13.62% |
| Sep 30, 2024 | 4,505.08% |
| Jun 30, 2024 | 48,275.00% |
| Mar 31, 2024 | 3,917.78% |
| Dec 31, 2023 | 642.60% |
| Sep 30, 2023 | 1,297.94% |
| Jun 30, 2023 | 763.21% |
| Mar 31, 2023 | 8,081.48% |
| Dec 31, 2022 | 1,084.18% |
| Sep 30, 2022 | 375.84% |
| Jun 30, 2022 | 12,400.00% |
| Mar 31, 2022 | 156.98% |
| Dec 31, 2021 | -145.42% |
| Sep 30, 2021 | -1,584.80% |
| Jun 30, 2021 | 680.57% |